Amer Zeidan: Looking Forward to Sharing New AML Data at ESH 2026
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn:
“I look forward to presenting in a podium talk the updated results from our KOMET 007 phase 1/2 study combining the novel oral menin inhibitor ziftomenib with intensive chemotherapy 7+3 in fit patients with newly diagnosed acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements at the European Society of Hematology meeting ESH2026 in Stockholm.
The early results from this study have led to the ongoing registrational-intent and global randomized phase 3 study KOMET 017 of the same combination which I am honored to be the steering committee chair and where at Yale University we were the first center to open and to enroll the first patient globally.”
Stay updated with Hemostasis Today.
-
May 19, 2026, 09:38Heghine Khachatryan: Why DVT in Elderly Patients Requires Special Attention?
-
May 19, 2026, 08:52Konstantin Stark: Announcing the Launch of Collaborative Research Center 1784 to Advance Thromboinflammation Research
-
May 19, 2026, 08:35Gokhan Ozdemir: Managing Acute Flow Diverter Stent Thrombosis in a Critical Vertebrobasilar Circulation
-
May 19, 2026, 08:28Rashad Falah: Evaluating Long Term Outcomes and Transfusion Risks in Obscure Gastrointestinal Bleeding
-
May 18, 2026, 16:35Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
-
May 18, 2026, 16:34Serah N. Gathu: Gaining Valuable Updates on ACS Management at the Africa STEMI Conference
-
May 18, 2026, 16:34Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
-
May 18, 2026, 16:33Dimitrios Kontothanassis: The Role of Thermal Ablation in GSV Reflux Treatment – LIVE 2026
-
May 18, 2026, 16:32Michael Lichardi: New Publication on Complex Anticoagulation Management in Critical Care